Is F a buy, hold, or sell?
F carries a valuation grade of Reduce. Our discounted cash flow model produces an intrinsic range of $11–$22 — implying a +18% margin of safety at the current price of $14.06. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
With a 9% beat rate on recent quarters, earnings predictability has been mixed. The most recent quarter delivered a 256.6% earnings surprise. Analyst estimate revisions are trending downward.
What are F's key risk factors?
With a beta of 1.80, F exhibits a highly aggressive risk profile relative to the broad market. The 95th-percentile CVaR of -19.0% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 1.9% of total portfolio loss in the worst 5% of months. Net margins of -3.2% fall below the Consumer Cyclical sector average of 10%, suggesting margin pressure. Debt-to-equity of 426% warrants monitoring for leverage risk.
At 0.52, the put/call ratio skews bullish, with call buyers dominating recent flow. Implied volatility of 36.7% is below realized volatility of 56.1%, potentially making options relatively cheap. Insider transactions show net buying of $3.9M over the trailing period, a signal often associated with management confidence.
How does F fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — F carries a beta of 1.80, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all reduceings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, F shows the strongest co-movement with CAT (0.30), TSLA (0.26), RIVN (0.25). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios.
True portfolio risk is a function of the full covariance structure across all reduceings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The F analysis here is a single node in that larger structure.
For the portfolio construction framework underpinning F’s position sizing and conviction rating — including IPS guardrails, Black-Litterman allocation, and CVaR constraints — see: Investment Policy Statement Framework →
